November 8, 2018 8:12am
In a continuing battle of consensus, expectation and estimates
Quarterly results: by Histogenics (HSGX), BioTime (NTSEMKT: BTX), Applied Genetic Technologies (AGTC), Intrexon (XON), BioLife Solutions (BLFS), Caladrius Bioscience (CLBS) and Biostage (BSTG)
Continuing thematic: “street” expectation – meeting or not?
Pre-open indications: 3 BUYs and 2 SELLs
A trusted source of factual reporting!
You should or could have been reading to facilitate your portfolios ... viability to flourish and produce gains!
Members only. Please login.